266 related articles for article (PubMed ID: 28728166)
1. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
Itamochi H; Oishi T; Oumi N; Takeuchi S; Yoshihara K; Mikami M; Yaegashi N; Terao Y; Takehara K; Ushijima K; Watari H; Aoki D; Kimura T; Nakamura T; Yokoyama Y; Kigawa J; Sugiyama T
Br J Cancer; 2017 Aug; 117(5):717-724. PubMed ID: 28728166
[TBL] [Abstract][Full Text] [Related]
2. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
3. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
[TBL] [Abstract][Full Text] [Related]
4. A clearer view on ovarian clear cell carcinoma.
De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT
Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027
[TBL] [Abstract][Full Text] [Related]
6. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
[TBL] [Abstract][Full Text] [Related]
7. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Chandler RL; Damrauer JS; Raab JR; Schisler JC; Wilkerson MD; Didion JP; Starmer J; Serber D; Yee D; Xiong J; Darr DB; Pardo-Manuel de Villena F; Kim WY; Magnuson T
Nat Commun; 2015 Jan; 6():6118. PubMed ID: 25625625
[TBL] [Abstract][Full Text] [Related]
8. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
[No Abstract] [Full Text] [Related]
9. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
[TBL] [Abstract][Full Text] [Related]
10. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J
Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863
[TBL] [Abstract][Full Text] [Related]
11. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
13. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
[TBL] [Abstract][Full Text] [Related]
14. Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma.
Marks EI; Brown VS; Dizon DS
Am J Clin Oncol; 2020 Feb; 43(2):139-145. PubMed ID: 31764020
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
16. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Jones S; Wang TL; Shih IeM; Mao TL; Nakayama K; Roden R; Glas R; Slamon D; Diaz LA; Vogelstein B; Kinzler KW; Velculescu VE; Papadopoulos N
Science; 2010 Oct; 330(6001):228-31. PubMed ID: 20826764
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C.
Kolendowski B; Valdes YR; Hirte H; Itamochi H; Lee W; Carey M; Shepherd TG; DiMattia GE
Cells; 2020 Nov; 9(11):. PubMed ID: 33153119
[TBL] [Abstract][Full Text] [Related]
19. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
Choi C; Kwon J; Lim S; Helfman DM
Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
[TBL] [Abstract][Full Text] [Related]
20. Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing.
Yang Q; Zhang C; Ren Y; Yi H; Luo T; Xing F; Bai X; Cui L; Zhu L; Ouyang J; Jiang P; Fan W; Qiu J; Wang F; Xing X; Zhang Z; Zhang X; Zhang R
Neoplasia; 2020 Sep; 22(9):399-430. PubMed ID: 32650224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
